Pfizer Inc (NYSE:PFE)
| 54.00 Delayed Data As of May 26 |  +0.29 / +0.54%Today’s Change | 38.48 Today|||52-Week Range 61.71 | -8.55% Year-to-Date |
Latest PFE News | Press Releases
| Why Novavax Was Tumbling by 12% This Week May 26 / MotleyFool.com - Paid Partner Content | Top 5 1st Quarter Trades of Sanders Capital, LLC May 25 / GuruFocus News - Paid Partner Content |
| Better Dividend Stock: Pfizer or Merck? May 26 / MotleyFool.com - Paid Partner Content | Pfizer (PFE) Reports More Positive Data From Etrasimod Study May 25 / Zacks.com - Paid Partner Content |
| Top 5 1st Quarter Trades of Sanders Capital, LLC May 25 / GuruFocus News - Paid Partner Content | Better Buy Ahead of FDA Meetings: Moderna vs. Novavax May 25 / MotleyFool.com - Paid Partner Content |
| Analysts Tab Veeva Systems as a Top Value Pick May 25 / GuruFocus News - Paid Partner Content | Sanders Capital, LLC Buys 2, Sells 3 in 1st Quarter May 24 / GuruFocus News - Paid Partner Content |
| How Vaccine Cash Could Fuel Pfizer's Future Growth May 25 / MotleyFool.com - Paid Partner Content | Top 5 1st Quarter Trades of CHELSEA COUNSEL CO May 24 / GuruFocus News - Paid Partner Content |
Today’s Trading
| Previous close | 53.71 |
| Today’s open | 53.99 |
| Day’s range | 53.89 - 54.91 |
| Volume | 23,516,309 |
| Average volume (3 months) | 29,863,010 |
| Market cap | $294.4B |
Data as of 4:00pm ET, 05/26/2022
Growth & Valuation
| Earnings growth (last year) | +128.42% |
| Earnings growth (this year) | +52.42% |
| Earnings growth (next 5 years) | -2.70% |
| Revenue growth (last year) | +93.97% |
| P/E ratio | 12.2 |
| Price/Sales | 4.15 |
| Price/Book | 3.82 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| LLYEli Lilly and Co | +6.46 | +2.10% |
| ABBVAbbVie | -1.37 | -0.90% |
| MRKMerck | -1.43 | -1.53% |
| AZNAstraZeneca | -0.13 | -0.19% |
Data as of 4:01pm ET, 05/26/2022
Financials
| Next reporting date | August 2, 2022 |
| EPS forecast (this quarter) | $1.81 |
| Annual revenue (last year) | $81.3B |
| Annual profit (last year) | $22.1B |
| Net profit margin | 27.57% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters New York, New York |
Forecasts
